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ABSTRACT
Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in containing the global tuberculosis
epidemic. Mycobacterium tuberculosis is intrinsically resistant to many antibiotics, limiting the number of compounds
available for treatment. This intrinsic resistance is due to a number of mechanisms including a thick, waxy, hydrophobic
cell envelope and the presence of drug degrading and modifying enzymes. Resistance to the drugs which are active against
M. tuberculosis is, in the absence of horizontally transferred resistance determinants, conferred by chromosomal mutations.
These chromosomal mutations may confer drug resistance via modification or overexpression of the drug target, as well as
by prevention of prodrug activation. Drug resistance mutations may have pleiotropic effects leading to a reduction in the
bacterium’s fitness, quantifiable e.g. by a reduction in the in vitro growth rate. Secondary so-called compensatory mutations,
not involved in conferring resistance, can ameliorate the fitness cost by interacting epistatically with the resistance
mutation. Although the genetic diversity of M. tuberculosis is low compared to other pathogenic bacteria, the strain genetic
background has been demonstrated to influence multiple aspects in the evolution of drug resistance. The rate of resistance
evolution and the fitness costs of drug resistance mutations may vary as a function of the genetic background.
Keywords: Mycobacterium tuberculosis; drug resistance; mechanisms; fitness; epistasis; evolution
ABBREVIATIONS
TB: Human tuberculosis
MDR: Multidrug-resistant – resistance to isoniazid and
rifampicin
XDR: Extensively drug-resistant – MDR + resistance to
fluoroquinolones and any of the second-line injectable
antibiotics (amikacin, kanamycin and capreomycin)
INTRODUCTION
Human tuberculosis (TB), a devastating disease caused by the
gram-positive, acid-fast eubacterium Mycobacterium tuberculo-
sis, was classified as a global health emergency by the World
Health Organization in 1993. TB remains one of the deadliest
infectious diseases with an estimated 1.8 million deaths oc-
curring per year, mainly in the developing world (World Health
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Organization 2016). Although the incidence of TB has declined
over the past decades, there were an estimated 10.4 million new
cases in 2015, of which 0.48 million were caused by M. tubercu-
losis strains classified as multidrug-resistant (MDR—resistant to
the first-line drugs rifampicin and isoniazid). Drug-resistant M.
tuberculosis strains are a major global health concern because
treatment of these cases requires second-line drugs, which are
less effective, more expensive andmore toxic, as well as sophis-
ticated infrastructure for drug susceptibility testing not read-
ily available in resource-limited settings. TB treatment success
rates of cases caused by MDR/XDR variants ofM. tuberculosis are
alarmingly low, with only 54% of MDR and 28% of extensively
drug-resistant (XDR—MDR plus resistance to fluoroquinolones
and any second-line injectable aminoglycoside/cyclic peptide)
cases resulting in cure, compared to 83% of drug-susceptible
cases (World Health Organization 2016). For clarity, we only refer
toMDR/XDRM. tuberculosis variants when the defined resistance
profiles are meant. Otherwise we use the term ‘drug resistance’
to refer to the topic in general, irrespective of specific drug re-
sistance profiles.
The first effective antituberculous drug, streptomycin, was
discovered in 1944 (Schatz, Bugle and Waksman 1944). The
newly discovered drug was immediately used for treatment of
TB patients. The condition of many individual TB patients re-
ceiving streptomycin improved during the first months of treat-
ment, only to then deteriorate again as treatment continued. It
was soon understood that this was due to the evolution of re-
sistant M. tuberculosis strains, rendering streptomycin ineffec-
tive (Crofton andMitchison 1948). To limit the evolution of resis-
tance, the British Medical Research Council pioneered the first
combination therapy for the treatment of a disease by using
para-aminosalicylic acid (Lehmann 1946) together with strepto-
mycin for treatment of pulmonary TB (Medical Research Coun-
cil 1950). The subsequent years saw the introduction of an array
of different antituberculous drugs. The discovery of rifampicin
in 1965 (Sensi 1983) and the subsequent use of the drug in TB
treatment was a game changer, allowing dramatically short-
ened treatment duration from 18 months or more to 9 months
(British Thoracic and Tuberculosis Association 1975). During the
1990s, the current standard 6-month regimen known as Directly
Observed Therapy Short Course (DOTS) was introduced by the
World Health Organization (World Health Organization 1997).
This regimen consists of 2 months treatment with isoniazid, ri-
fampicin, ethambutol and pyrazinamide followed by 4 months
of isoniazid and rifampicin (World Health Organization 1991),
and is highly effective for drug-susceptible TB (Frieden et al. 1995;
Feng-Zeng et al. 1996).
A short treatment duration and reduction of adverse drug
effects are crucial for increasing patient treatment adherence,
which is known to influence the evolution of drug resistance
(Mahmoudi and Iseman 1993). However, despite the early estab-
lishment of TB combination therapies showing high cure and
low relapse rates (British Thoracic and Tuberculosis Association
1975), drug-resistant M. tuberculosis strains continued to evolve
in both high and low incidence settings.MDRM. tuberculosis vari-
ants evolved onmultiple occasions in different parts of theworld
(Cohen et al. 2015; Eldholm et al. 2015). Furthermore, differences
in the quality of public health systems contributed to the spread
of drug-resistant M. tuberculosis variants leading to the unequal
distribution of incidence rates of drug-resistant variants around
the world we observe today (World Health Organization 2016).
In the absence of an effective vaccine (Kaufmann et al. 2014),
there is an urgent need for new treatment regimens, drugs and
diagnostics to slow the evolution of drug resistance and limit
transmission of resistant variants, as well as to ameliorate the
treatment outcome of patients infected with MDR/XDRM. tuber-
culosis strains. Understanding the molecular mechanisms and
the evolutionary trajectory of drug resistance is important to
limit the de novo evolution and subsequent spread of resistantM.
tuberculosis strains. The first part of this review will summarise
intrinsic and acquired mechanisms of drug resistance in M. tu-
berculosis; these are analysed in more detail in several recently
published reviews (Smith, Wolff and Nguyen 2013; Zhang and
Yew 2015; Nash 2016; Nguyen 2016). The second part of this re-
viewwill focus on our current understanding of the evolutionary
biology of drug resistance in M. tuberculosis.
MECHANISMS OF DRUG RESISTANCE
IN MYCOBACTERIUM TUBERCULOSIS
Members of the genus Mycobacterium have long been noted for
their intrinsic resistance to a wide array of antibiotics. This has
mainly been attributed to the unusually thick, lipid-rich cell en-
velope (Jarlier and Nikaido 1994). After penetrating the cell enve-
lope, certain antibiotics may be cleaved enzymatically or altered
structurally to render them ineffective (Chambers et al. 1995;
Quinting et al. 1997; Wang, Cassidy and Sacchettini 2006; War-
rier et al. 2016). Furthermore, a number of efflux systems have
been identified in M. tuberculosis, but their significance in con-
ferring clinically relevant levels of drug resistance is a matter of
debate. As efflux systems have been observed to be expressed
under varying conditions (Gupta et al. 2010; Adams et al. 2011; Li
et al. 2015), they might serve as a stepping stone for high-level
drug resistance. A further peculiarity ofM. tuberculosis is the ap-
parent absence of ongoing horizontal gene transfer (Cole et al.
1998; Gagneux and Small 2007; Bolotin and Hershberg 2015). Al-
though there have been reports of horizontal gene transfer be-
tween ‘species’ of the genusMycobacterium (da Silva Rabello et al.
2012), horizontal gene transfer does not seem to be a driving fac-
tor in the acquisition of antimicrobial resistance inM. tuberculo-
sis. The vast majority of drug resistance phenotypes in M. tuber-
culosis can be explained by chromosomal mutations and not by
resistance plasmids or other mobile genetic elements. To study
themechanisms of drug resistance,many studies have been per-
formed on amultitude of differentmycobacterial species, due to
the often lower pathogenicity/biosafety requirements and faster
growth properties of these mycobacteria compared to M. tuber-
culosis. The most widely used model is M. smegmatis, an envi-
ronmental mycobacterium with a genome roughly 1.5 times the
size of that ofM. tuberculosis.We should therefore be cautious in
applying the results of these studies directly to M. tuberculosis.
INTRINSIC DRUG RESISTANCE IN
MYCOBACTERIUM TUBERCULOSIS
The mycobacterial cell wall and drug penetration
The intrinsic resistance of mycobacteria against several classes
of antibiotics has commonly been attributed to the unusual
composition and structure of the mycobacterial cell envelope.
Compared to other gram-positive bacteria, the cell wall of mem-
bers of the genus Mycobacterium is much thicker and more hy-
drophobic, due to the presence of a wide array of different
lipids that include mycolic acids. Many studies (reviewed in
Jarlier and Nikaido 1994; Brennan and Nikaido 1995; Nguyen
and Pieters 2009; Sarathy, Dartois and Lee 2012) performed in
different mycobacterial species demonstrated that the com-
position of the cell envelope and the low numbers of porins
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(Mailaender et al. 2004) contribute significantly to the cell en-
velope’s low compound permeability. A major constituent of
the cell wall is a layer of lipids, which are covalently linked to
the peptidoglycan layer via arabinogalactan. Furthermore, the
cell wall contains ‘extractable’ immunogenic glycolipids (Bren-
nan and Nikaido 1995). The lipid-rich nature renders the cell
wall extremely hydrophobic and prevents the permeation of
hydrophilic compounds. It is thought that small hydrophilic
compounds, including many antibiotics active against M. tuber-
culosis, can only traverse the cell wall via water-filled porins.
Heterologous expression of the M. smegmatis porin MspA in M.
tuberculosis did indeed decrease the minimal inhibitory concen-
tration for several hydrophilic drugs (Mailaender et al. 2004),
indicating that porins might play a role in the diffusion of hy-
drophilic antibiotics across the cell wall of M. tuberculosis. How-
ever, until recently reports on the presence of porins inM. tuber-
culosiswere lacking. The outer membrane channel protein CpnT
was demonstrated to be involved in nutrient uptake in M. bovis
BCG and M. tuberculosis (Danilchanka et al. 2014) and in mediat-
ing susceptibility to nitric oxide and antibiotics in M. bovis BCG
(Danilchanka et al. 2015). CpnT seems to be under positive se-
lection in clinical M. tuberculosis isolates, demonstrated by the
overrepresentation of non-synonymous mutations in the gene
encoding CpnT (Rv3903c). However, the role of CpnT in medi-
ating drug susceptibility to hydrophilic antibiotic compounds in
M. tuberculosis needs further investigation, as CpnT deletionmu-
tants do not demonstrate drug resistance phenotypes in vitro.
However, the studies confirm the presence of porins in the outer
membrane of M. tuberculosis and their role in uptake of small
hydrophilic compounds. Furthermore, the physical organisa-
tion of the cell wall lipids is believed to limit the membrane’s
fluidity. A recent study (Rodriguez-Rivera et al. 2017) assessed
the membrane fluidity in live cells of M. smegmatis and other
actinobacteria by measuring the reorganisation of fluorescein-
labelled therealose analogues bymycolyltransferases. The study
demonstrated that, compared to other actinobacteria, M. smeg-
matis has the lowest membrane fluidity. This is thought to be
a function of mycolic acid structure (length and presence of
functional groups). Interestingly, exposure of M. smegmatis to
subinhibitory concentrations of ethambutol increases themem-
brane’s fluidity and diffusion of compounds across the cell
envelope. This offers the possibility for novel drug combina-
tion therapies, as the reduction of the membrane fluidity using
ethambutol can render M. tuberculosis susceptible against drug
classes it is normally resistant against (Abate and Hoffner 1997;
Bosne-David 2000).
The peculiar characteristics of the mycobacterial cell en-
velope hinder the diffusion of hydrophobic molecules includ-
ing members of several antibiotics belonging to the classes
of macrolides, rifamycins, tetracyclines and fluoroquinolones
(Brennan and Nikaido 1995). However, it does appear that the
rate of diffusion is a function of molecule hydrophobicity to
a certain extent, with hydrophobic molecules diffusing more
readily through the mycobacterial cell envelope (Rastogi and
Goh 1990; Nikaido and Thanassi 1993). The hypothesis that the
cell envelope lipids are a major factor in the intrinsic resistance
of mycobacteria to many hydrophobic antibiotics is further sub-
stantiated by studies performed with mutants defective in lipid
synthesis, which are susceptible to drugs that the correspond-
ing wild-type strain is resistant against (Liu and Nikaido 1999).
A recent study modelled the permeation of compounds through
the mycobacterial cell wall and demonstrated that lipophilicity
is an important but not exclusive factor of compound perme-
ability (Janardhan, Ram Vivek and Narahari Sastry 2016).
Drug inactivation by Mycobacterium tuberculosis
After penetrating the cell wall as an initial defence layer, antibi-
otics may be cleaved enzymatically to render them ineffective.
One of the most prominent examples is the enzymatic degra-
dation of β-lactam antibiotics by β-lactamases, which hydrolyse
the β-lactam ring of the antibiotics. Early studies involving peni-
cillin demonstrated that M. tuberculosis is intrinsically resistant
to this class of antibiotics (Abraham et al. 1941). The genome of
M. tuberculosis encodes a single class A β-lactamase termed BlaC
thought to localise to the periplasmatic space, either anchored
in the outer leaflet of the plasma membrane as a lipoprotein
or unbound. The M. tuberculosis β-lactamase shows broad sub-
strate specificity (including carbapenems), albeit with varying
affinities, and is considered an extended-spectrum β-lactamase.
BlaC is irreversibly inhibited by the β-lactamase inhibitor clavu-
lanate (Wang, Cassidy and Sacchettini 2006; Hugonnet and Blan-
chard 2007). Due to the increasing numbers of cases caused by
MDR/XDR M. tuberculosis strains, there has been a renewed in-
terest in the use of β-lactam antibiotics in the treatment of
TB. An early, small study reported no beneficial effect of in-
cluding an amoxicillin/clavulanate combination in a salvage
regimen (a regimen of last resort with unproven efficacy) to
treat patients infected with MDR M. tuberculosis strains (Yew
et al. 1995). Since then, several in vitro (Chambers et al. 1995;
Hugonnet et al. 2009) and in vivo studies (Payen et al. 2012; De
Lorenzo et al. 2013) reported encouraging results on treatment
outcomes with various regimens by including β-lactam antibi-
otics with clavulanate. However, some MDR/XDR M. tuberculosis
isolates still appear to be resistant to mereponem/clavulanate
or amoxcicillin/clavulanate without harbouring any mutations
that could explain the observed variability in susceptibility to
these drugs (Cohen et al. 2016). The true value of β-lactam an-
tibiotics for the treatment of drug-resistant M. tuberculosis vari-
ants still needs further assessment. Given the positive results
in diverse studies, the demonstrated safety profile of β-lactam
antibiotics/β-lactamase inhibitors and the limited treatment op-
tions for MDR/XDR TB warrants further investigation into treat-
ment regimens including this class of antibiotics.
Apart from drug cleavage, antibiotics may be inactivated by
modification, e.g. bymethylation or acetylation. To date, the best
described mechanism of drug inactivation by chemical modifi-
cation inM. tuberculosis is the acetylation of various aminoglyco-
side/cyclic peptide antibiotics used for the treatment of MDR TB
by the enhanced intracellular survival protein (Eis). Eis has been
demonstrated to acetylate and inactivate the clinically relevant
second-line injectable aminoglycoside antibiotic kanamycin A
(Zaunbrecher et al. 2009), as well as the cyclic peptide antibiotic
capreomycin (Houghton et al. 2013). Several promotormutations
identified in clinical M. tuberculosis isolates lead to overexpres-
sion of Eis, which in turn confers low-level resistance against
kanamycin A but not amikacin (Zaunbrecher et al. 2009; Kam-
bli et al. 2016). It is not clear if Eis overexpression alone leads to
clinically relevant levels of capreomycin resistance (Kambli et al.
2016). Overexpression of Eis therefore might serve as a stepping
stone for the evolution of high-level aminoglycoside/cyclic pep-
tide resistance.
Recently, a novelmechanismof drug inactivationwas discov-
ered inM. tuberculosis. The pyrido-benzimidazole compound ‘14’
was described as having potent bactericidal activity against aer-
obically growing M. tuberculosis (Warrier et al. 2015). Compound
14 may be N-methylated by a previously unknownmethyltrans-
ferase encoded by the gene Rv0560c. The methylated compound
14 is unable to inhibit its target, the decaprenylphosphoryl-β-D-
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ribose 2-oxidase (DprE1), which is involved in arabinogalactan
synthesis (Warrier et al. 2016). Although this is a novel mech-
anism of drug resistance in M. tuberculosis, and in bacteria in
general, it has no known clinical relevance to date.
Enzymatic drug target modification
Many antibiotics in use are natural products produced by bac-
teria, which requires the producing bacteria to be resistant to
these compounds; some of the mechanisms used by these bac-
teria are conserved in mycobacteria. Streptomyces spp. produce
diverse classes of antibiotics, e.g. macrolides, lincosamides and
streptogramins. These antibiotics inhibit the bacterial ribosome
by binding to the 50S ribosomal subunit. Streptomyces spp. are
resistant to these antibiotics by expressing methyltransferases
which mono- or dimethylate the adenosine residue 2058 (Es-
cherichia coli notation) of the 23S rRNA, preventing the afore-
mentioned drugs from binding to the ribosome and inhibiting
translation. The M. tuberculosis genome encodes the methyl-
transferase Erm(37), a homologue of Erm methyltransferases
found in many actinomycetes. However, the substrate speci-
ficity of Erm(37) differs from its homologues—Erm(37) is able to
monomethylate residues 2057–2059 of the 23S rRNA, instead of
only residue 2058. Monomethylation of positions 2057–2059 con-
fers resistance to variousmacrolide antibiotics (Buria´nkova´ et al.
2004; Madsen et al. 2005).
Drug efflux in Mycobacterium tuberculosis
Efflux systems are important constituents of bacterial and eu-
karyotic physiology.Multiple reviews have been published (Louw
et al. 2009, 2011; da Silva et al. 2011; Warrell 2012; Anthony
Malinga and Stoltz 2016) focusing on efflux systems in M. tu-
berculosis; the main points are briefly summarised here. Early
comparative studies revealed that the genome of M. tuberculo-
sis encodes a multitude of different putative efflux systems, be-
longing to the classes of ATP-binding cassette, major facilitator
superfamily, small multidrug resistance, multidrug and toxic-
compound extrusion systems and resistance-nodulation-cell di-
vision (Paulsen et al. 2001).
The relevance of drug efflux for generating clinically relevant
drug resistance in M. tuberculosis is controversial but has gained
more attention in recent years. The observation that about 30%
of isoniazid (Louw et al. 2009) and 3% of rifampicin (Telenti et al.
1993) resistant clinical M. tuberculosis isolates do not show any
known resistance mutation might be explained by drug efflux.
However, this unexplained resistance is potentially confounded
by the fact that not all mutational targets of drug resistance are
known. For certain antibiotics e.g. isoniazid, an array of different
resistance mechanisms is already known (Vilche`ze and Jacobs
2014). On the other hand, resistance to rifampicin is thought
only to be conferred bymutations in the gene encoding one con-
stituent of the drug target (further discussed below), making the
contribution of efflux pumps to unexplained resistance pheno-
types more likely.
Efflux pumps exhibit high levels of substrate promiscuity
and are able to extrude a multitude of structurally unrelated
compounds. Furthermore, efflux systems have been shown
to be essential in M. tuberculosis for intracellular growth in
macrophages (Lamichhane, Tyagi and Bishai 2005). Mycobac-
terial efflux pumps are able to extrude nearly all antituber-
culous drugs, including streptomycin, rifampicin, isoniazid,
clofazimine, bedaquiline, fluoroquinolones and ethambutol
(Anthony Malinga and Stoltz 2016). Expression of efflux pumps
can be viewed as a plastic trait, meaning that expression lev-
els are modified via non-mutational processes upon changes in
the environment. We can therefore say that efflux pumps are
induced or upregulated when a specific environmental cue (e.g.
antibiotics or the intracellular environment of a macrophage) is
present. The term ‘overexpression’ should only be used for mu-
tants where expression levels exceed the reaction norm (box 1)
of the wild-type strains. To our knowledge, there have not been
any studies systematically investigating the reaction norm of ef-
flux pumps in M. tuberculosis.
Box 1. Definitions of commonly used terms in evolu-
tionary biology.
Bottleneck
A bottleneck describes the stark reduction of the population
size and therefore the genetic diversity of the population
due to random sampling, i.e. genetic drift. In the context of
M. tuberculosis infections, only a subset of the whole popu-
lation of bacteria present in the lungs of a patient will gain
access to the airways and may be aerosolised. Furthermore,
presumably only a subset of that aerosolised populationwill
survive the harsh environmental conditions found outside
of the host, and is able to infect a newhost—if one is present
to inhale the aerosols.
Effective population size
In the context of bacterial (haploid), non-recombining, obli-
gate pathogens like M. tuberculosis, the effective population
size describes the proportion of the population e.g. in a pa-
tient, which has the possibility to transmit to a new host.
Mycobacterium tuberculosis is able to establish infections in
nearly all tissues—however, all of them are ‘evolutionary
dead ends’, pulmonary (or in rare cases laryngeal) infections
being the only exception. Consider the case of a patient with
pulmonary and extrapulmonary TB. The effective popula-
tion size could be defined as the total number ofM. tuberculo-
sis cells present in a patientminus the number of cells in the
extrapulmonary location, ergo the pulmonary (laryngeal)M.
tuberculosis population—as only this population will be able
to transmit to a new host. Furthermore, transmission of M.
tuberculosis requires substantial lung damage that ‘allows’
access to the bronchi, which is dependent on the location
of the foci within the lung, ergo not all M. tuberculosis cells
in the lung will have the potential to transmit, reducing the
effective population size.
Epidemiological cutoff
The highest minimal inhibitory concentration of a drug ob-
served in a wild-type strain. This is related to the reaction
norm—see below.
Epistasis
Epistasis describes the phenomenon where the interaction
of two or more genes/alleles produce an effect on the phe-
notype (e.g. on fitness) which is unequal to the sum each
gene’s/allele’s effect on their own.
Fitness
The fitness of an organism can be defined as the ability to
survive and reproduce in a given environment. In the case
of an obligate parasite like M. tuberculosis, this entails es-
tablishing an infection in the human host, replicating and
transmitting to a new host. Fitness can be parameterised by
the effective reproductive number R, which quantifies how
many secondary cases are produced on average by a sin-
gle infected individual in a population of susceptible and
resistant hosts. However, R is notoriously difficult to assess
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in vivo. In absence of a better measure, fitness of bacteria
is often approximated by measuring life history traits e.g.
in vitro growth rates and/or growth yield in artificial growth
media. However, there is some merit in measuring in vitro
growth rates/yields e.g. of resistant M. tuberculosis variants
as their growth rate/yields are often correlated with in vivo
frequency of these variants.
Fitness cost
A fitness cost describes the reduction in the number of
offspring produced by a genotype in a given environment
caused e.g. by a drug resistance mutation, compared to a
drug-susceptible variant. Drug resistance has long been as-
sumed to be generally associated with a fitness cost in ab-
sence of the drug (i.e. a reduction in R, the number of sec-
ondary cases generated). Using in vitro methods, a fitness
cost would manifest itself as a reduction in growth rate or
yield.
Genetic background
The genetic background describes the genetic di-
versity present in a strain’s genome resulting from
mutations/insertions/deletions/rearrangements etc. when
compared to other strains. The genetic background is an
important factor influencing epistatic interactions.
Genetic drift
Genetic drift is an important mechanism of evolution
whereby the genetic diversity of a population is reduced by
random sampling error. The sampling error results from the
differential probability of an organism to survive and repro-
duce based on chance. The effect of genetic drift on allele
frequencies is strongest in populations with a small effec-
tive population sizes. Genetic drift can lead to the stochastic
fixation or loss of alleles in a given population.
Natural selection
Natural selection is one of the major mechanisms of evo-
lution and refers to the differential survival of organ-
isms based on their phenotype. The phenotype results
from the interaction of the organism’s genotype with the
environment. The differential survival results from compe-
tition (e.g. for resources) among organisms and is depen-
dent on the degree of adaptation of the organism to its en-
vironment. The effect of natural selection is strongest in
large populations and leads to changes in allele frequencies
over time.
Mutational target size
Themutational target size in the narrow sense describes the
number of differentmutations whichmay confer resistance
to a certain drug. Depending on the resistance mechanism,
the mutational target size can vary greatly. The mutational
target size in the broader sense describes the number of dif-
ferent mutations which confer resistance to a given drug
and which do not result in lethality due to epistatic interac-
tions with the strain genetic background.
Reaction norm
The phenotype of an organism results from the interac-
tion of the organism’s genotype with the environment. The
range of different phenotypes of a given genotype in differ-
ent environments is called the reaction norm (Griffiths et al.
2005).
Standing genetic diversity
The term standing genetic diversity describes the presence
of multiple alleles at a locus which are segregating in the
population. In other words, the sum of all genetic back-
grounds (see above) constitutes the standing genetic diver-
sity of a species.
Trait effect
Hall et al. describe the trait effect as e.g. the effect drug resis-
tance mutations may have on life history traits like growth
rate and/or yield of the strains carrying resistance muta-
tions. The magnitude of the trait effect inflicted by drug re-
sistancemutations is dependent onmultiple factors includ-
ing the genetic background, pre-existing drug resistance
mutations, compensatory mutations and the environment
(Hall et al. 2015).
It has been demonstrated in model systems ofM. tuberculosis
that efflux pumps are induced upon infection of macrophages,
which coincides with increased minimal inhibitory concentra-
tions for isoniazid (Adams et al. 2011). A subset of the strainswas
resistant to higher levels of isoniazid at the peak serum concen-
trations (Park et al. 2016). The expression of the efflux systems
persists even after the mycobacterial cells have been released
from themacrophages. However, in accordancewith the concept
of efflux pumps as a plastic trait, not all bacterial cells upregulate
the expression of efflux systems (Gupta et al. 2010; Adams et al.
2011). Several antituberculous drugs have been demonstrated to
induce the expression of efflux pump genes, but there is con-
siderable variability between strains and no general pattern of
efflux pump expression was recognisable (Gupta et al. 2010). Fur-
thermore, MDR M. tuberculosis isolates have been shown to con-
stitutively express genes involved in drug efflux (Li et al. 2015).
Although there are reports on the upregulation of efflux systems
generating minimal inhibitory concentrations slightly beyond
the epidemiological cutoff (box 1), the clinical relevance of ef-
flux pumps is not clear andwarrantsmore investigation (Adams
et al. 2011). The majority of drug-resistant strains harbour chro-
mosomalmutations linked to drug resistance (further discussed
below). However, there are examples of clinically relevant lev-
els of resistance conferred by ‘overexpression’ of efflux pumps.
Mutations in the transcriptional repressor MmpR lead to overex-
pression of the multisubstrate efflux pump Mmpl5 (Milano et al.
2009), which coincides with cross-resistance to clofazimine and
the new antituberculous drug bedaquiline (Hartkoorn, Uplekar
and Cole 2014; Bloemberg et al. 2015). As Mmpl5 is also involved
in isoniazid extrusion, MmpRmutants are likely also to be resis-
tant to isoniazid (Milano et al. 2009).
However, efflux systems may act as a stepping stone for the
evolution of high-level resistance, as convincingly demonstrated
by in vitro studies (Machado et al. 2012; Schmalstieg et al. 2012).
As efflux pumps seem to be essential for macrophage infec-
tion (Lamichhane, Tyagi and Bishai 2005), efflux pump inhibitors
might be used to inhibit bacterial growth and lower the MICs for
certain drugs (Pule et al. 2016).
ACQUIRED DRUG RESISTANCE IN
MYCOBACTERIUM TUBERCULOSIS
Apart from the intrinsic resistance mechanisms mentioned
above, the majority of clinically relevant drug resistance in M.
tuberculosis is conferred by chromosomalmutations. These chro-
mosomal mutations confer drug resistance via a large array of
different mechanisms and may confer different levels of resis-
tance (Fig. 1). The most common targets of chromosomal mu-
tations conferring drug resistance are summarised in Table 1.
Depending on the antibiotic in question, there may be multiple
mechanisms of resistance.
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Figure 1. Levels of drug resistance conferred by different mechanisms. The red
cross indicates a chromosomal mutation. (a) Low-level resistance due to induc-
tion of efflux pumps. Depiction of efflux pumps is omitted later stages for clar-
ity. (b) Low-level resistance due to target overexpression caused by chromoso-
malmutation. (c) High-level resistance due to drug targetmodification conferred
by chromosomal mutation. (d) High-level resistance due to overexpression and
modification of drug target conferred by independent chromosomal mutations.
Drug target alteration
The most common mechanism of drug resistance in M. tubercu-
losis is drug target alteration. Interactions of drug and drug target
moieties are highly specific. Changes in the drug–drug target in-
teraction sites may reduce or completely abolish drug binding
and therefore confer resistance to the drug in question. Non-
synonymousmutations in drug target encoding gene(s) (Table 1)
or nucleotide substitutions in the operon encoding the riboso-
mal RNA are frequently observed to confer drug resistance inM.
tuberculosis as in the case of resistance against rifamycins, isoni-
azid, fluoroquinolones, aminoglycosides, cyclic peptides, para-
aminosalicylic acid and oxazolidinones (e.g. linezolid). For ex-
ample, mutations in the active site of the DNA-dependent RNA
polymerase, corresponding to the 81 bp region known as the
rifampicin resistance determining region, confer resistance to
rifampicin, by decreasing the affinity of rifampicin for target
(Campbell et al. 2001). Antibiotics target essential cellular func-
tions and the drug targets performing these functions are highly
conserved. The highly conserved nature of the drug targets lim-
its the mutational target size (box 1) as the resistance mutation
has to accomplish two things: first, it has to prevent the antibi-
otic from inhibiting the target and second it must ensure that
the essential function of the drug target can still be performed.
Inmany but not all cases this leads to a reduction in the bacterial
cell’s fitness in absence of the drug.
Abrogation of prodrug activation
Several antimycobacterial drugs are prodrugs, and abrogation
of the drug-activating mechanisms leads to resistance as in
the case of the first-line drugs isoniazid and pyrazinamide, the
second-line drugs ethionamide and para-aminosalicylic acid, as
well as the two new nitroimidazole drug candidates delamanid
and pretomanid. In certain cases, the prodrug-activating en-
zyme is not essential for mycobacterial growth and survival (e.g.
pncA/ddn; Table 1). The target size for drug resistance-conferring
chromosomal mutations is therefore large—many point muta-
tions, insertions/deletions, insertion of mobile genetic elements
etc. will cause disruption of the prodrug-activating gene product
without compromising bacterial survival. Furthermore, muta-
tions in the promoter of the gene might lead to lower transcript
and therefore lower levels of the enzyme activating the prodrug.
Lower levels of the prodrug-activating enzyme will then in turn
lead to higher minimal inhibitory concentrations for the drug in
question.
In pyrazinamide-resistant M. tuberculosis strains, we ob-
serve a wide array of different mutations in the gene pncA
which encodes the enzyme metabolising pyrazinamide to its
active form pyrazinoic acid. The mutational target size for de-
lamanid/pretomanid resistance is considerably larger as multi-
ple enzymes and cofactors are involved in the metabolism of
prodrugs to their active forms. This suggests that resistance
to the latter two drugs may evolve swiftly due to the large
mutational target size (box 1). On the other hand, the gene
katG encoding a catalase/peroxidase involved in the activation
of isoniazid is required for robust replication of M. tuberculo-
sis in macrophages (Manca et al. 1999). The mutational target
size for isoniazid resistance is small, compared to pyrazinamide
or delamanid/pretomanid. The resistance-conferring mutation
in katG must retain the (in vivo) essential function of the en-
zyme (catalase/peroxidase—detoxification) as well as prevent
the activation of isoniazid. Most clinical M. tuberculosis isolates
harbour the point mutation katG S315T which retains most
catalase/peroxidase functions as well as conferring high-level
isoniazid resistance (Pym, Saint-Joanis and Cole 2002). On the
other hand, KatG is not essential for in vitro replication—this
greatly enlarges the mutational target size for in vitro resistance,
as any mutation disrupting the function of KatG will lead to re-
sistance (Bergval et al. 2009).
Overexpression of drug targets
Overexpression of the drug target may overcome the inhibition
by the drug in question due to an overabundance of the target.
Mutations in transcriptional repressors or the promoter of the
drug target may cause the overexpression of the drug target as
in the case of isoniazid, ethambutol and cycloserine. Drug target
overexpression confers low-level resistance (e.g. to isoniazid or
cycloserine), which usually can be overcome by increasing the
dosing of drugs administered. Drugs are administered at fixed
doses, often adjusted for patient weight/age. This is generally
done to achieve the maximum effectiveness of the drug whilst
minimising adverse effects of administered drugs. As certain an-
tibiotics (e.g. cycloserine; Desjardins et al. 2016) show dramatic
adverse effects, the dose given to patients is reduced asmuch as
possible, whichmeans there is little room for increasing the drug
doses to overcome resistance due to drug target overexpression.
Overexpression of drug targets may serve as a stepping stone
to high-level resistance, which is conferred either by drug target
alteration or abrogation of prodrug activation (Fig. 1).
EVOLUTION OF DRUG RESISTANCE IN
MYCOBACTERIUM TUBERCULOSIS
The evolution of drug-resistant M. tuberculosis variants has gen-
erally been attributed to inadequate implementation of control
measures, interrupted drug supply, low-quality drugs and pa-
tient non-adherence. However, it is increasingly evident that
these factors alone are insufficient to explain the evolution of
drug resistance in TB, as resistant M. tuberculosis strains evolve
in well-functioning health systems and under strict treatment
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Table 1. List of the most common targets of chromosomal mutation conferring drug resistance in M. tuberculosis.
Antibiotic Target gene Resistance mechanism Reference
Rifampicin rpoB Drug target alteration Telenti et al. (1993)
Isoniazid katG Abrogated prodrug activation Heym et al. (1995)
inhA Drug target alteration Banerjee et al. (1994); Morlock et al. (2003); Hazbo´n et al. (2006)
inhA promotor Drug target overexpression Morlock et al. (2003); Hazbo´n et al. (2006)
Ethambutol embB Drug target alteration Sreevatsan et al. (1997)
Pyrazinamide pncA Abrogated prodrug activation Konno, Feldmann and McDermott (1967); Scorpio and Zhang (1996)
Ethionamide inhA Drug target alteration Banerjee et al. (1994); Morlock et al. (2003); Hazbo´n et al. (2006)
inhA promotor Drug target overexpression Morlock et al. (2003; Hazbo´n et al. (2006)
ethA Abrogated prodrug activation Morlock et al. (2003)
Fluoroquinolones gyrA/B Drug target alteration Takiff et al. (1994); Xu et al. (1996); Malik et al. (2012)
Streptomycin rrs Drug target alteration Meier et al. (1994); Maus, Plikaytis and Shinnick (2005a)
rpsL Drug target alteration Nair et al. (1993); Meier et al. (1994)
Amikacin rrs Drug target alteration Alangaden et al. (1998); Maus, Plikaytis and Shinnick (2005a)
Kanamycin A rrs Drug target alteration Alangaden et al. (1998)
eis promotor Overexpression of drug
inactivating enzyme
Kambli et al. (2016)
Capreomycin rrs Drug target alteration Maus, Plikaytis and Shinnick (2005a)
tlyA Abrogation of drug target
methylation
Maus, Plikaytis and Shinnick (2005b); Monshupanee et al. (2012)
P-aminosalicylic acid thyA Drug target bypassing Zhao et al. (2014); Minato et al. (2015)
folC Abrogation of prodrug
activation
Zhao et al. (2014); Minato et al. (2015)
Cycloserine ald Overabundance of drug target
substrate
Desjardins et al. (2016)
alr Drug target alteration Desjardins et al. (2016)
alr promotor Drug target overexpression Desjardins et al. (2016)
Bedaquiline atpE Drug target alteration Huitric et al. (2010)
Promotor/mmpR Overexpression of efflux
pump Mmpl5
Hartkoorn, Uplekar and Cole (2014); Bloemberg et al. (2015)
Linezolid rplC Drug target alteration Beckert et al. (2012)
rrl Drug target alteration Hillemann, Rusch-Gerdes and Richter (2008)
Delamanid/pretomanid ddn Abrogation of prodrug
activation
Manjunatha et al. (2006); Bloemberg et al. (2015); Haver et al. (2015)
fgd1 Abrogation of prodrug
activation
fbiA/B/C Abrogation of prodrug
activation
Clofazimine Promotor/mmpR Overexpression of efflux
pump Mmpl5
Hartkoorn, Uplekar and Cole (2014); Bloemberg et al. (2015)
adherence (Caminero 2008; Calver et al. 2010). Pathogen and host
determinants are increasingly recognised to influence the evolu-
tion of drug resistance. For instance, the emerging field of phar-
macogenomics has demonstrated that the current dosage regi-
men for TB treatment fails to generate sterilising concentrations
of certain antituberculous drugs in all patients and may con-
tribute to treatment failure, as well as facilitate the evolution
of drug resistance (Gumbo 2010; Swaminathan and Ramachan-
dran 2012). Furthermore, recent studies have demonstrated that
there is considerable variability in drug penetration into TB le-
sions, generating spatial and temporal variation in drug concen-
trations within the infected lung (Prideaux et al. 2015). It is well
established that subinhibitory drug concentrations facilitate the
evolution of drug resistance (Gillespie et al. 2005; Gullberg et al.
2011; Andersson and Hughes 2014), and heterogeneity between
and within patients maymean that some TB cases are being un-
wittingly exposed to subinhibitory treatment regimes.
Although the genusMycobacterium in general andM. tubercu-
losis in particular show low genetic diversity compared to other
bacteria (Achtman 2008), the standing genetic diversity (box 1)
exhibited by M. tuberculosis translates into phenotypic diversity.
There are seven extant M. tuberculosis lineages, which demon-
strate specific phylogeographic patterns. Lineages 5 and 6 are
restricted toWest Africa and lineage 7 to the Horn of Africa. Lin-
eage 1 is found along the rim of the Indian Ocean and lineage 3
is predominantly found in East Africa and South Asia. Lineage 4
and to a lesser extent lineage 2 are globally distributed (Borrell
and Gagneux 2011; Coscolla and Gagneux 2014). Lineage 2 and
lineage 4 have been frequently associated with drug resistance
(Fenner et al. 2012; Cohen et al. 2015).
To better understand the de novo evolution of drug resistance,
it is helpful to separate the different processes involved. The rate
of evolution of resistance (Ford et al. 2013) and the effect of drug
resistance on bacterial life history traits like growth rate/yield
may differ as a function of the strain genetic background. Drug
resistance is often associated with reduction in bacterial fitness
(box 1) in the absence of the drug. This reduction is, however,
not universal and can vary as a function of the genetic back-
ground (Gagneux et al. 2006c). The fitness cost of drug resistance
may be ameliorated by secondary, so-called compensatory mu-
tations, which do not contribute to resistance on their own (Co-
mas et al. 2011; Casali et al. 2012; de Vos et al. 2013; Hughes and
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Brandis 2013). Furthermore, several drug resistance-conferring
mutations present in a single strain might interact epistatically
(box 1) and influence bacterial fitness (Gagneux et al. 2006c; Bor-
rell et al. 2013). This means that the strain genetic background,
compensatory mutations and the presence of multiple resis-
tance mutations may interact to influence the fitness of drug-
resistant M. tuberculosis strains (Fig. 3).
The spread andmaintenance of resistant variants in the pop-
ulation not only depends on the effect of drug resistance on the
bacterial life history traits, but is also strongly dependent on the
pathogen’s population structure and effective population size,
as well as genetic drift (box 1). In the case of M. tuberculosis, ge-
netic drift is thought to strongly influence the genetic diversity
of the organism, as the effective population size is believed to be
small and subject to large bottlenecks during patient-to-patient
transmission (box 1) (Hershberg et al. 2008).
DE NOVO EVOLUTION OF DRUG RESISTANCE
There are three important factors influencing the de novo evolu-
tion of drug resistance: the population size, as it relates to the
number of binary fission events the population has undergone;
the mutation rate; and the mutational target size (box 1). To-
gether, these factors determine the rate of resistance acquisi-
tion. The strain genetic background may influence any of these
parameters. It is, however, not trivial to determine the contribu-
tion of each of the factors, as they are either difficult to study in
vivo or are not independent of each other.
Population size
In a series of iconic experiments, Luria and Delbru¨ck demon-
strated that, for simple traits (e.g. most bacteriophage/antibiotic
resistance), bacterial populations which undergo a sufficient
number of doubling events inevitably harbour resistant variants,
followingwhat is now called a Luria-Delbru¨ck distribution (Luria
andDelbru¨ck 1943). The larger the population, themore cell divi-
sion events the population experienced, and therefore the larger
probability for a drug resistance mutation to arise. Furthermore,
if a resistance-conferring mutation evolves early during popu-
lation expansion, the vast majority of the population will be
resistant to a given drug even before treatment onset. We unfor-
tunately do not have good estimates of the number of Mycobac-
terium tuberculosis cells present in human lungs during infection.
The number of bacteria present in a single lesion is estimated to
be in the order of 108 bacterial cells per lesion (Shimao 1987), al-
though it is not clear what the basis of this estimate is. The best
estimates of viable M. tuberculosis cells were obtained from the
lungs of cynomolgusmacaques (Macaca fasicularis) infected with
M. tuberculosis. The disease presentation in macaques resem-
bles that observed in humans. The study demonstrated that a
macaque lung contains anything between ≈ 105 and 5×108 cells,
depending on the individual macaque (Lin et al. 2009). However,
most monkeys did not develop cavitary disease. It is believed
thatM. tuberculosismay reach very high cell densitieswhen repli-
cating on the interior surface of open (i.e. with access to the
airways) lung cavities, but the exact cell numbers have, to our
knowledge, never been assessed in humans. There is evidence
that drug-resistant M. tuberculosis variants are predominantly
found where cell densities are high, i.e. at the interior of cavi-
tating granulomas (Kaplan et al. 2003). It is exceedingly difficult
to obtain reliable estimates of bacterial cell numbers in the lungs
of TB patients. Recent studies have highlighted that the dis-
ease presentation in the lung is far more dynamic as previously
believed (reviewed in Lenaerts, Barry and Dartois 2015). The
number of granuloma cannot be directly used to estimate the
number of bacterial cells present in a patient lung, as there is
a large diversity of microenvironments within granuloma and
not all environments allow bacterial replication. However, if we
solely focus on cavitating granuloma, we might be able to use
disease severity, i.e. the number and extent of cavitations as
a very rough proxy for population size. The fewer the cavities
present in a patient’s lung, the smaller the population size of tu-
bercle bacilli. There are reports of differences between lineages
in terms of disease severity (reviewed in Coscolla and Gagneux
2010, Coscolla and Gagneux 2014). Lineages 2 and 4, especially
the so-called Beijing sublineage of lineage 2, have been associ-
ated with more severe disease presentation compared to other
lineages. TheM. tuberculosis lineages 2 and 4 are also associated
with drug resistance (Pardini et al. 2009; Niemann et al. 2010;
Mokrousov et al. 2012; Ford et al. 2013; Casali et al. 2014; Cohen
et al. 2015; Merker et al. 2015). Differences in bacterial population
sizes between lineages might therefore contribute to the differ-
ential association of specific lineages with drug resistance.
In general, we can say that the probability of evolving resis-
tance is dependent on the number of binary fission events. M.
tuberculosis is an intracellular pathogen and its primary niche
is the macrophage. Although M. tuberculosis is able to survive
and replicate inside macrophages, the tubercle bacteria seem
to be inhibited in growth when the bacterial numbers are small
(Welin et al. 2011). It is not clear if this is due to killing or growth
inhibition by the macrophage. However, there is evidence that
the innate immune system is able to clear M. tuberculosis infec-
tions before the onset of adaptive immunity (Verrall et al. 2014).
It is therefore likely that a proportion of the tubercle bacilli are
killed by the macrophage. This means that aM. tuberculosis pop-
ulation of a given size has likely undergone more binary fission
events than expected from exponential growth, as the immune
system continuously removes bacterial cells from the popula-
tion. As killing of tubercle bacilli by macrophages is likely to oc-
cur stochastically, one can view this as a form of genetic drift
(box 1), potentially slowing the rate of drug resistance evolution.
A recent study demonstrated that there are differences in the
replication potential between differentM. tuberculosis lineages—
lineage 2 and 4 being proficient in replicating in macrophages,
and strains belonging to lineage 3 and Mycobacterium africanum
less so (Reiling et al. 2013). However, it is not clear if the high cell
densities observed in macrophages infected with M. tuberculosis
strains belonging to lineage 2 and 4 are due to better survival
in the macrophage or faster growth or both. In conclusion, it is
not entirely clear if there is substantial variability in terms of
number of binary fission events between lineages of M. tubercu-
losis. The recent adaptation of a fluorescence dilution assay to
M. tuberculosis offers the exciting possibility to assess the num-
ber of doubling events and the extent of cell death experienced
by mycobacterial bacilli during macrophage infection (Helaine
et al. 2016). Measuring growth properties of different M. tubercu-
losis lineages in an ex vivo system will help to clarify if there are
differences between lineages concerning the number of binary
fission events and therefore the rate of drug resistance evolu-
tion.
Mutation rates
The mutation rate is thought to be largely defined by the repli-
cation fidelity of the bacterial DNA polymerases. The basal mu-
tation rate of M. tuberculosis is difficult to study as the long
generation time makes mutation accumulation experiments
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unfeasible. Aworkaround is expressing theM. tuberculosisDnaE1
DNA polymerase heterologously in M. smegmatis. The genera-
tion time of M. smegmatis is much lower compared to M. tu-
berculosis, but it has the drawback that the effect of the ge-
netic background (box 1) on mutation rates cannot be taken
into account. Using the heterologeous DnaE1 expression ap-
proach, the mutation rate has been determined to be 4.52 ×
10−10 (2.95–7.35 × 10−10 95% confidence interval) per bp and gen-
eration, which is on the lower end of the spectrum compared
to other bacteria (Rock et al. 2015). Other studies have assessed
the mutation rate using whole genome sequencing (Ford et al.
2011). However, there are potentially many more factors influ-
encing the mutation rate, including the intracellular environ-
ment of macrophages which are rich in reactive oxygen and
nitrogen species, expression of error-prone DNA polymerases
(DnaE2) due to the stressful macrophage environment, enzymes
involved in repair–replication–recombination, existing drug re-
sistancemutations, exposure to UV radiation and/or desiccation
during aerosolisation (McGrath et al. 2014).
Mutational target size
Given a mutation rate, the number of potential sites which may
be mutated to confer drug resistance is an important factor in-
volved in determining the rate of drug resistance evolution. As
mentioned earlier, the mutational target size varies depend-
ing on resistance mechanism (box 1). The mutational target
size for prodrugs activated by non-essential enzymes is much
larger compared to the target sizes for mutational drug tar-
get alteration. The mutational target size for drug target alter-
ation is in the range of 81 bp in the gene rpoB for rifampicin
resistance (Musser 1995) and 117 bp in the gene gyrA for flu-
oroquinolone resistance (Maruri et al. 2012). The majority of
resistance-conferring mutations are found in these regions in
clinico (Sandgren et al. 2009). Furthermore, the number of muta-
tions conferring drug resistance is dependent on the resistance
level in question. Drug resistancemutations differ in the level of
resistance they confer. There is an inverse relationship between
the drug resistance level that mutations confer and the muta-
tional target size—the higher the selective concentration, the
smaller the target size, i.e. there are fewer mutations conferring
high-level than low-level resistance (Ford et al. 2013). Drug re-
sistance mutations interact epistatically with the genetic back-
ground of a strain—a given drug resistance mutation may have
different trait effects (box 1) in different genetic backgrounds.
This may lead to a reduction in the mutational target size in
the broader sense when the interaction of a resistance muta-
tion with the strain genetic background results in a detrimental
trait effect in absence of the selective agent.
Rate of drug resistance acquisition
The rate of drug resistance acquisition is defined by the muta-
tion rate and themutational target size in the broader sense and
may be calculated by Luria-Delbru¨ck fluctuation assays (Luria
and Delbru¨ck 1943). In the past, there has been considerable de-
bate on the influence of the genetic background on the rate of
resistance acquisition. As mentioned previously, lineage 2 and
lineage 4 have been disproportionately associated with drug re-
sistance. It was found previously that M. tuberculosis strains be-
longing to lineage 2 carry mutations in genes involved in DNA
replication, repair and recombination (Mestre et al. 2011), poten-
tially elevating mutation rates. However, this would imply that
lineage 2 in general should demonstrate greater average genetic
diversity compared to other lineages, which does not appear to
be the case (Coscolla and Gagneux 2014). Multiple studies have
focused on the rate of resistance acquisition in M. tuberculosis.
The rate of resistance acquisition is influenced by the basal mu-
tation rate and the mutational target size in the broader sense.
Some studies report differences in resistance acquisition rates
between lineages, where strains from the Beijing sublineage of
lineage 2 show higher rates of resistance acquisition compared
to other lineages (de Steenwinkel et al. 2012; Ford et al. 2013),
others reported similar rates between lineages (Werngren and
Hoffner 2003). If there are differences in the rate of resistance
acquisition between lineages, this could indicate that the muta-
tional target size in the broader sense is different between lin-
eages. Even if the results are discrepant, we are still missing a
large part of the picture. Due to the labour-intensive nature of
conducting Luria-Delbru¨ck fluctuation assays with M. tuberculo-
sis, most studies have so far focused on the rate of acquisition of
resistance to rifampicin; there are few data available on differ-
ences in drug resistance acquisition rates between lineages for
other drugs commonly in use to treat TB.
De novo evolution of drug resistance and treatment
with drug combinations
TB cases caused by drug-susceptible M. tuberculosis strains are
treated with a combination of four drugs to limit the evolu-
tion of drug resistance, as a strain would need to acquire at
least four independent resistance mutations in order to achieve
high-level resistance, which is theoretically unlikely to happen
if the M. tuberculosis bacilli carry no pre-existing resistance mu-
tations and are exposed to all drugs at the same time. However,
in some patients the tubercle bacilli evolve drug resistance de-
spite strict treatment adherence (Calver et al. 2010). This may
be caused by functional monotherapy and/or subinhibitory drug
concentrations as discussed above, known to facilitate the evo-
lution of drug resistance (Gillespie et al. 2005; Andersson and
Hughes 2014). Suboptimal drug concentrations can arise due to
the differential potential of certain drugs to penetrate bacte-
ria containing lesions in the human lung. For instance, pyraz-
inamide and rifampicin have been demonstrated to be able to
diffuse and accumulate in the hypoxic and acidic granuloma,
whereas the other first-line drugs do not accumulate in these
structures (Prideaux et al. 2015). These processes are likely to
generate spatial and temporal variation in drug concentrations,
facilitating the evolution of drug resistance (Moreno-Gamez et al.
2015). Drug penetration into TB lesions is dependent on multi-
ple factors including lipophilicity and solubility. Detailed knowl-
edge of the chemical properties needed for effective distribu-
tion throughout allM. tuberculosis containing lesions will aid the
design of novel, more effective antituberculous drug regimens
(Dartois 2014).
Drug resistance levels and the strain genetic
background
Apart from the rate of resistance evolution, the genetic back-
groundmay influence the level of resistance conferred by a drug
resistance mutation. In the case of isoniazid resistance, it has
been shown that the level of resistance conferred by different
mutations varies with the genetic background ofM. tuberculosis,
whereby the isoniazid resistancemutation katG S315T conferred
lower levels of resistance in strains belonging to lineage 1 com-
pared to lineages 2, 3 and 4 (Fenner et al. 2012). This phenomenon
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could also contribute to different mutational target sizes in the
broader sense in different genetic backgrounds (Ford et al. 2013).
Depending on the concentration of the drug, fewer resistance
mutations might be available to certain lineages, which in turn
would lower the rate of resistance evolution.
FITNESS OF DRUG-RESISTANT
MYCOBACTERIUM TUBERCULOSIS STRAINS
Drug resistance was long believed to be universally associated
with a reduction in the drug-resistant organism’s fitness in the
absence of antibiotics (box 1). In the case of mycobacteria, this
dogma was established by early studies performed with iso-
niazid resistant M. tuberculosis variants. These studies demon-
strated a marked reduction in virulence of certain, but not all,
isoniazid resistant strains in guinea pigs and mice (Barnett,
Busby and Mitchison 1953; Middlebrook and Cohn 1953). The
observation that most drug resistance is associated with a re-
duction in fitness is further corroborated by studies performed
in other pathogenic microorganisms (Melnyk, Wong and Kassen
2015). Early mathematical models predicted that MDR-TB would
remain a localised public health problem (Dye and Espinal 2001;
Dye 2002). Hence, initially, the World Health Organization rec-
ommended focusing on DOTS for patients with drug-susceptible
TB and against treating patients infected with MDR M. tubercu-
losis strains, as treating these patients is exceedingly expensive
and the MDR strains were not believed to transmit enough to
establish a sustainable infection chain (Espinal and Dye 2005).
Mathematical models predict that the probability of a drug-
resistant strain spreading in the absence of antibiotic pressure is
largely dependent on the resistant variant’s reproductive fitness
(Blower and Chou 2004; Cohen and Murray 2004; Luciani et al.
2009; Knight et al. 2015). The ultimate measure of fitness would
be the effective reproductive number R (box 1), which measures
the average number of secondary cases generated per infected
individual in a population of susceptible and resistant hosts. The
effective reproductive number R is a high-level composite mea-
sure comprising all aspects concerning transmission, including
pathogen, host and environmental factors. Changes in R due to
drug resistancemutations can lead to changes in allele frequen-
cies over time. However, assessing R in vivo requires prospective
cohort studies which are labour intensive and expensive to con-
duct. Although cohort studies allow assessment of epidemiolog-
ical factors associated with transmission, they often suffer from
small sample sizes and are restricted to a single setting relevant
for transmission (e.g. households).
To better study the impact of drug resistance on the fitness
(i.e. R) of M. tuberculosis, it is helpful to separate the effect of
drug resistance on bacterial life history traits—the trait effect
(box 1), from effects of drug resistance on allele frequencies in
the population—the selective effect (Hall et al. 2015). Trait ef-
fects of drug resistance mutations may be assessed by mea-
suring life history traits like growth rate/yield of drug-resistant
M. tuberculosis variants in vitro. Drug resistance mutations may
have diverse pleiotropic effect on bacterial physiology resulting
in a reduced in vitro growth (Fig. 2). However, this reduction in
growth yield/rates is not universal; it is strongly dependent on
the mechanism of resistance, as well as the specific mutation
in question. Furthermore, there is a strong effect of the strain
genetic background on the fitness costs. Fitness costs may be
ameliorated by secondary, so-called compensatory mutations,
which do not contribute to drug resistance on their own. Com-
pensatory mutations may lead to the retention of drug-resistant
Figure 2. Fitness of drug resistant M. tuberculosis strains in absence of the drug.
Solid arrows indicate the trajectories of drug resistance. Dashed arrow indicates
the unlikely possibility of reversion. The red cross indicates a chromosomal mu-
tation. (a) Induction of efflux pumps at no orminimal fitness cost. (b) Large varia-
tion in fitness costs due to resistance via chromosomalmutations—ranging from
very low/no to lethal. The observed variation may arise due to epistatic interac-
tions of the strain genetic background and the resistance mutation(s). (c) Varia-
tion in fitness levels of strains harbouring secondary compensatorymutations—
ranging from comparable to wild-type levels to slightly below.
M. tuberculosis variants in the population in absence of selec-
tive pressure due to the drug. Epistatic interactions between the
genetic background and the resistance-conferring mutations
seem to be pervasive and an important determinant in shaping
the population biology of drug-resistantM. tuberculosis variants.
Measuring in vitro fitness of drug resistancemutations as a proxy
for in vivo fitness has been criticised for not capturing the com-
plex dynamics involving nutrient limitation, activity of the im-
mune system, host genetics and comorbidities (Bjo¨rkman et al.
2000). However, the frequency of resistance alleles in the popula-
tion correlates well with the in vitro fitness of the strains carrying
mutations for rifampicin, fluoroquinolone and aminoglycoside
resistance in laboratory adapted, as well as in clinical M. tuber-
culosis isolates (Bo¨ttger et al. 1998; Sander et al. 2002; Gagneux
et al. 2006c; Bo¨ttger and Springer 2008; Borrell et al. 2013). How-
ever, all in vitro fitness cost assessments are based on the ability
of theM. tuberculosis strain being able to readily grow in artificial
growth media. It is well established that not all bacilli present
in patient sputumwill demonstrate in vitro growth. This is prob-
lematic as our frequency estimates for drug resistance alleles are
based on culturing M. tuberculosis bacilli from patient sputum,
isolating genetic material and subsequent sequencing. How-
ever, there is no a priori reason to assume that the frequencies
of drug resistance mutations are different in the populations
of culturable and unculturable bacilli. Culture-freemetagenomic
approaches will offer a less biased view on the frequencies of
drug resistance mutations present in the lungs (sputa) of TB pa-
tients (Koch, Mizrahi and Warner 2014).
In vitro fitness of drug-resistant Mycobacterium
tuberculosis strains
There are two methods for assessing in vitro fitness of resis-
tant variants: growth rate measurements and competition as-
says. Growth rate assessment focuses on the replication rate of
a strain during exponential growth in absence of any drug pres-
sure. In competition assays, the resistant variant is co-cultured
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with the susceptible wild-type strain for one or several bacte-
rial growth cycles in absence of the drug. At the endpoint of the
experiment, the ratio of resistant to susceptible variants is as-
sessed. Bothmethods allow calculation of selection coefficients.
The advantage of competition assays is that they take growth
yield as well as growth rate into account. Selection on growth
rate occurs when there is no population structure and resources
are freely available to all individuals. On the other hand, growth
yield is favoured in structured populations where resources are
restricted and efficiency in nutrient utilisation is favoured (Frank
2010). Populations of M. tuberculosis in human lungs have been
thought of as highly structured, as observed by the concurrent
presence of strains carrying different resistance mutations in
separate parts of the infected lung (Kaplan et al. 2003; Post et al.
2004; Lieberman et al. 2016).
Several studies have investigated the effect of drug resis-
tance mutations on in vitro fitness of M. tuberculosis or M. smeg-
matis either using competition assays or growth rate assess-
ments. These studies have focused on assessing the impact of
rifampicin (Gagneux et al. 2006c; Song et al. 2014), aminoglyco-
side (Sander et al. 2002; Freihofer et al. 2016) and fluoroquinolone
(Borrell et al. 2013) resistance on the bacterium’s fitness com-
pared to the susceptible ancestor in absence of the drug. We do
not have reliable data on isoniazid resistance as the in vitro re-
sistance mechanism differs from that observed in vivo (Bergval
et al. 2009). However, there is reason to assume that there are
no or very low fitness costs of the most frequent isoniazid resis-
tance mutation (katG S315T), as M. tuberculosis variants carrying
this mutation transmit efficiently and are virulent in mice (van
Soolingen et al. 2000; Pym, Saint-Joanis and Cole 2002; van Doorn
et al. 2006; Gagneux et al. 2006a). For the same reasons we do not
have reliable data on the fitness of clinical MDR/XDR strains. We
are restricted to measuring the fitness of such strains relative to
each other, rather than to their cognate drug-susceptible ances-
tor (Spies et al. 2013; Naidoo and Pillay 2014).
Most rifampicin resistance mutations carry a significant fit-
ness cost in M. tuberculosis (Billington, McHugh and Gillespie
1999; Mariam et al. 2004; Gagneux et al. 2006b; Koch, Mizrahi
and Warner 2014) (Fig. 2). However, there are some mutations
(e.g. rpoB S450L—M. tuberculosisnotation; Andre et al. 2017) which
only cause a small defect in fitness. There seems to be some in-
fluence of the genetic background on the cost of rifampicin resis-
tance, whereby lineage 2 experiences smaller reductions in fit-
ness compared to lineage 4 (Gagneux et al. 2006c). Interestingly,
the fitness costs of rifampicin resistance are elevated under
nutrient-restricted conditions (Song et al. 2014). Nutrient limita-
tion is pervasive in the human host, indicating that there will be
strong selection against costly drug resistance mutations. Fluo-
roquinolone resistancemutations show varying degrees of costs
in M. smegmatis (Borrell et al. 2013). Some mutations conferring
fluoroquinolone resistance even show a fitness benefit, but this
could be an artefact of the in vitro assessment conditions. Most
aminoglycoside resistance is also costly. There are, however, also
resistancemutationswhich do not demonstrate any discernable
fitness cost (Sander et al. 2002; Freihofer et al. 2016). The effect
of the strain genetic background on the fitness cost of amino-
glycoside resistance is yet to be determined. The in vitro fitness
of MDR and especially XDR M. tuberculosis strains is variable.
Some strains demonstrate very low replication rates, whilst oth-
ers replicate at rates similar to drug-susceptible strains (Spies
et al. 2013; Naidoo and Pillay 2014). However, it is striking that
combinations of low-cost resistance mutations rifampicin (rpoB
S450L—M. tuberculosis notation) and isoniazid (katG S315T) in
MDR/XDR strains are frequently observed in clinico. TB caused
Figure 3. Pervasive epistatic interactions influencing the physiology and popula-
tion biology of drug-resistantM. tuberculosis strains. The effect of drug resistance
mutations alone or in combination as well as the presence of compensatorymu-
tations affects the fitness of drug-resistant M. tuberculosis strains as a function
of the strain genetic background.
by XDR M. tuberculosis strains is a rather new phenomenon. It
is thought that most XDR M. tuberculosis isolates arise due to
de novo evolution rather than transmission (Gandhi et al. 2006;
Casali et al. 2014). The isolation of XDR M. tuberculosis strains
with very low replication rates could reflect the fact that se-
lection has not yet removed the most unfit XDR strains from
the population. However, it is remarkable that there is a strong
association of MDR/XDR strains with lineages 2 and 4 (Pardini
et al. 2009; Niemann et al. 2010; Mokrousov et al. 2012; Ford et al.
2013; Casali et al. 2014; Cohen et al. 2015; Merker et al. 2015). This
might indicate that strains belonging to these lineages experi-
ence lower fitness costs due to drug resistance. On the other
hand, lineages 2 and 4 are also the most widespread. The asso-
ciation of these lineages with drug resistance could just be due
to the large numbers of TB patients infected with strains from
these lineages. To elucidate if the frequent association of lin-
eages 2 and 4with drug resistance is due to lower fitness costs of
drug resistance experienced by these strains, we need detailed
assessments of the population structures of drug-resistant and
susceptible M. tuberculosis strains over time.
Compensation of fitness costs
Fitness costs caused by drug resistance mutations may be ame-
liorated by secondary so-called compensatorymutations (Fig. 2).
These mutations do not contribute to drug resistance directly.
Fitness cost compensation results from the epistatic interaction
of the compensatory mutation with the drug resistance muta-
tion and the genetic background of the strain (Fig. 3, box 1). Fit-
ness cost compensation is poorly understood. Whole genome
sequencing studies have demonstrated that MDR and especially
XDR strains tend to harbour a multitude of mutations (Zhang
et al. 2013; Merker et al. 2015). A high proportion of these mu-
tations are thought to have functional consequences. As these
strains are resistant tomany antibiotics, the reportedmutations
can be speculated to be involved in compensation of fitness
costs. To date, we knowof three distinctmechanisms involved in
the compensation of fitness costs (Andersson and Hughes 2010).
First, secondary mutations in the genes encoding the drug tar-
get might restore or improve the mutated enzyme’s function to
levels comparable to the wild-type enzyme (Comas et al. 2011;
Casali et al. 2012; Hughes and Brandis 2013). To be classified as a
putative compensatory mutation, these mutations should only
be found in resistant strains and never in susceptible strains.
However, only fitness measurements can confirm or refute the
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compensatory role of the mutation. Second, overexpression of
an enzyme which performs a similar function to the drug target
may compensate for the diminished or abolished function of the
drug target (Sherman et al. 1996; Heym et al. 1997). Third, non-
mutational gene regulatory responses may compensate for the
fitness defect inflicted by the resistancemutation (Freihofer et al.
2016). However, the latter case is a form of phenotypic plasticity
and the term ‘buffering’ of fitness costs would be more appro-
priate than compensation.
Compensatory evolution has been demonstrated to occur
very frequently for rifampicin resistance (Comas et al. 2011;
Casali et al. 2012; Hughes and Brandis 2013). Fitness costs of ri-
fampicin resistance due to mutations in the β ′-subunit of DNA-
dependent RNA polymerase encoded by rpoB can be compen-
sated by mutations in rpoA/B/C. The molecular basis of fitness
costs and their compensation in rifampicin-resistantM. tubercu-
losis strains is not well understood. However, studies performed
with rifampicin-resistant Pseudomonas aeruginosa have indicated
that rifampicin resistance mutations in rpoB reduce the tran-
scriptional efficiency of the DNA-dependent RNA polymerase
and may explain the observed fitness costs. Compensatory mu-
tations restored the transcriptional efficiency to wild-type levels
in rifampicin-resistant strains (Qi, Preston and MacLean 2014).
The connection between transcriptional efficiency and in vitro
growth rate (fitness cost) seems plausible in fast-growing bac-
teria like P. aruginosa. However, it remains to be demonstrated
that fitness costs inflicted bymutations in rpoB are caused by re-
duced transcriptional efficiency in slow-growing bacteria likeM.
tuberculosis. Interestingly, the compensatorymutations are often
found at the interface between the different RNA polymerase
subunits. More specifically, the compensatory mutations home
to positions in the vicinity of the active site and the RNA exit
tunnel (Song et al. 2014). Compiling data from several studies
(Comas et al. 2011; de Vos et al. 2013; Farhat et al. 2013; Lanzas
et al. 2013; Mu¨ller et al. 2013; Casali et al. 2014; Song et al. 2014;
Bloemberg et al. 2015; Eldholm et al. 2015; Merker et al. 2015),
rifampicin resistance mutations in rpoB and putative compen-
satory mutations in rpoA/B/C offer some striking insights. In M.
tuberculosis, most compensatorymutations in rpoA/C (Fig. 4b and
c) are associated with the most clinically frequent rifampicin
resistance mutation rpoB S450L (Fig. 4a and d). The rifampicin
resistance-conferring mutation rpoB S450L consistently shows
the lowest fitness cost in vitro (de Vos et al. 2013; Casali et al.
2014; Cohen et al. 2015; Meftahi et al. 2016). There are two non-
exclusive explanations for this observation. First, the low av-
erage fitness cost of rpoB S450L might offer a large mutational
spectrum for compensation, i.e. there are a multitude of differ-
entmutations in rpoA/B/Cwhich compensate for the fitness cost
of rpoB S450L.More costly rifampicin resistancemutationsmight
have a more restricted mutational target for compensation. An
alternative explanation would be a sequential nature of resis-
tance and compensatory mutation acquisition. Mycobacterium
tuberculosis strains carrying rpoB S450L are able to outcompete
other rifampicin resistance mutations due to its low cost. This
will lead to an overabundance of M. tuberculosis strains carrying
the rpoB S450Lmutation in the population, making it more likely
for these strains to acquire compensatory mutations. Loss-of-
function mutations in the gene katG are known to confer re-
sistance to isoniazid (Table 1). However, the catalase/peroxidase
activity of KatG is essential for efficient in vivo growth ofM. tuber-
culosis. Besides KatG, the genome of M. tuberculosis encodes the
peroxidase AhpC. Certain clinical isoniazid-resistantM. tubercu-
losis strains have been noticed to harbourmutations in the regu-
latory regions of the gene ahpC, which leads to overexpression of
AhpC. However, it was noticed that overexpression of ahpC does
not compensate for the reduction in virulence observed in katG
deletion mutants. Overexpression of ahpC might therefore only
partially restore the fitness costs of katG deletions by enhanc-
ing detoxification of detrimental reactive oxygen species (Sher-
man et al. 1996; Heym et al. 1997). Recently, a non-mutational
mechanism of fitness cost compensation was described. Upreg-
ulation of tlyA expression in capreomycin-resistantM. tuberculo-
sis strains was found to partially compensate (buffer) the fitness
cost inflicted by the mutation conferring resistance to capre-
omycin (Freihofer et al. 2016). Resistance to capreomycin can
be conferred by mutations in the ribosomal RNA (Table 1). The
gene tlyA encodes a methyltransferase which methylates nu-
cleotides of the ribosomal RNA. Methylation of the ribosomal
RNA nucleotide directly adjacent to the resistance conferring
mutated nucleotide seems to partially restore fitness levels (Frei-
hofer et al. 2016). Mitigation of fitness costs via non-mutational
processes can be viewed as a plastic trait.
In vivo fitness of drug-resistant Mycobacterium
tuberculosis strains
Although in vitro fitness measurements have provided us with
valuable estimates of the fitness costs inflicted by drug resis-
tance, the ultimate measure incorporating all steps from estab-
lishing an infection to transmission ofM. tuberculosis is captured
by the effective reproductive number R (box 1). Several studies
have attempted to approximate R by conducting prospective co-
hort studies. These have mainly focused on the number of sec-
ondary cases generated in households of TB patients infected
with drug-susceptible or drug-resistant M. tuberculosis strains.
These studies (reviewed in Fox et al. 2013) have revealed conflict-
ing results, with some showing considerably lower transmission
rates among MDR vs susceptible M. tuberculosis strains and oth-
ers showing comparable transmission rates. The heterogeneity
in the determined transmission rates might reflect differences
in study design.
Household contact studies are expensive and labour in-
tensive to conduct. A more convenient and powerful way of
assessing the in vivo fitness of drug-resistant M. tuberculosis
strains is a population-based high-resolution genotyping study.
The combination of whole genome sequencing together with
high-quality epidemiological data will allow assessment of
transmission rates at high spatial and temporal resolution.
Several studies have already demonstrated the value of
whole genome sequencing for inferring transmission networks
(Walker et al. 2013; Casali et al. 2014; Luo et al. 2014; Hatherell
et al. 2016; Yang et al. 2016).
Epistatic interactions between drug resistance
mutations
TB infections are always treated with a combination of drugs.
There is therefore strong selection for M. tuberculosis strains
which are concomitantly resistant to several drugs used for
treatment. The effect of multiple drug resistance mutations on
the organism’s phenotype is dependent on the epistatic interac-
tions of the different resistance mutations with each other and
with the genetic background of the strain. Certain combinations
of resistance mutations may therefore be especially favoured if
they do not confer a fitness deficit. Due to the vast number of
different combinations of different drug resistancemutations, it
is difficult to assess the contribution of different combinations
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Figure 4. Summary of rifampicin resistance and fitness cost compensatory mutations in rpoB and rpoA/C respectively. (a) Frequency of rifampicin resistance mutations
in rpoB. (b) Frequency of putative compensatory mutations in rpoC in codons 420–540. (c) Frequency of putative compensatory mutations in rpoA in codons 170–200.
(d) Association of rifampicin resistance mutations in rpoB with putative compensatory mutations in rpoA/C.
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of resistance mutations to the phenotype experimentally, es-
pecially in M. tuberculosis. However, assessing allele frequencies
from clinical isolates may inform us about successful vs detri-
mental combinations of drug resistance alleles.
Several drugs target the information pathway from DNA
to mRNA to proteins by inhibiting key enzymes involved in
these processes. Mutations in these enzymes alone or in com-
bination have pleiotropic effects on the fitness of M. tubercu-
losis. Infections with MDR M. tuberculosis strains are treated
with drug regimens containing fluoroquinolones. Per definition
these strains are resistant to isoniazid and rifampicin. Fluoro-
quinolone resistance mutations will therefore mostly evolve in
rifampicin-resistant M. tuberculosis strains. Rifampicin targets
the DNA-dependent RNA polymerase and fluoroquinolones tar-
get the DNA-gyrase and these two enzymes work in concert.
Studies performed with M. smegmatis demonstrated that de-
pending on the combination of rifampicin and fluoroquinolone
resistance mutation, the effects on the in vitro growth rate
range from detrimental to even beneficial. This goes so far,
that fitness cost of a resistance mutation is fully compensated
by the presence of a second resistance mutation. In certain
cases, the double-resistant strain had an even faster growth
rate than the drug-susceptible wild type. Combinations of the
most beneficial resistance alleles are also the most frequent in
clinical M. tuberculosis isolates (Borrell et al. 2013). In vitro stud-
ies have demonstrated that pre-existing isoniazid resistance
mutations influence which rifampicin resistance mutations are
subsequently acquired. This is probably due to a reduction in
the mutational target size in the broader sense (box 1) due
to epistatic interactions between the two resistance-conferring
mutations, resulting in a dramatic reduction in fitness of spe-
cific combinations (Bergval et al. 2012). Streptomycin inhibits the
bacterial ribosome, and resistance is often conferred by muta-
tions in the gene rpsL. Streptomycin was the first active antitu-
berculous drug in use and resistance to this drug is widespread.
Household contact studies have determined that M. tuberculosis
strains harbouring the streptomycin resistance-conferring mu-
tation rpsL K43R together with the isoniazid resistancemutation
katG S315T generated significantly fewer secondary cases indi-
cating an epistatic interaction between the streptomycin and
isoniazid resistance mutations resulting in a fitness cost (Sal-
vatore et al. 2016). However, this is in contrast to other studies,
which have found that the combination of rpsL K43R with katG
S315T does not reduce fitness ofM. tuberculosis harbouring these
mutations (Spies et al. 2013). These discrepancies demonstrate
the large variability in these interactions, highlighting the influ-
ence of the strain genetic background on all these interactions.
In turn, drawing general conclusions from rather small datasets
is not possible or at best challenging.
POPULATION GENETICS OF DRUG RESISTANCE
IN MYCOBACTERIUM TUBERCULOSIS
The forces of evolutionmay determine the fate of drug-resistant
M. tuberculosis variants at multiple stages during infection. Dur-
ing transmission, M. tuberculosis populations undergo stark bot-
tlenecks (box 1) as new infections are thought to be established
only by a few bacilli (Jacobs 1941). Thismeans that inmost cases,
the bacterial populations in the lungs of TB patients will demon-
strate only very low levels of genetic diversity. Only about 12%
of all infections with M. tuberculosis will result in active disease
within the life time of a patient (Dheda, Barry and Maartens
2016). After the formation of the primary complex, M. tubercu-
losis bacilli are disseminated throughout the lung where they
form new foci. The bacteria present in these foci are thought to
form isolated subpopulations with little migration between the
populations, at least in the early stages of the infection. Struc-
tured populations are thought to select for growth yield optimi-
sation, as they do not have to compete for resources with other,
faster growing variants due to the private nature of the resources
(Frank 2010). Indeed, sampling bacteria fromdifferent lesions re-
vealed the presence of distinct subpopulations throughout the
lungs of TB patients (Lieberman et al. 2016). However, sampling
M. tuberculosis bacteria from patient sputum during treatment at
different time points revealed a dynamic picture of the bacterial
population. Multiple different resistance alleles e.g. conferring
resistance to fluoroquinolones were present concomitantly—a
phenomenon known as heteroresistance. Furthermore, certain
drug resistance alleles were increasing over time whilst others
were disappearing.Moreover, therewas selection for strains har-
bouring less costly resistance and/or known compensatory mu-
tations (Merker et al. 2013; Eldholm et al. 2014; Bloemberg et al.
2015; Bernard et al. 2016). Selection for M. tuberculosis variants
with higher growth rates might indicate that resources avail-
able in a patient’s lung are not private and that the bacterial
populations are less structured than we had anticipated. In-
deed, studies performed in cynomolgus macaques and TB pa-
tients (Lin et al. 2013; Coleman et al. 2014) demonstrate a much
more dynamic picture. During the course of M. tuberculosis in-
fection, existing foci have been observed to be eliminated by
the immune system, whereas new foci seem to appear, with-
out any discernable pattern. The immune system is apparently
able to eliminate foci and presumably kill the bacteria present
in these lesions. The removal of bacteria from these lesions
by the immune system can be viewed as a form of genetic
drift. This has implications for the de novo evolution of drug re-
sistance. Populations of de novo evolved resistant M. tuberculo-
sis variants inevitably start out with low numbers. Populations
with small effective population sizes are vulnerable to extinc-
tion by genetic drift. This means that the action of the immune
system might slow the de novo evolution of drug resistance,
by stochastically removing resistant variants from the popula-
tion. Host-directed therapies (Zumla et al. 2015) boosting the ac-
tion of the immune system in clearing TB infections will in-
evitably also reduce the rate at which drug-resistant variants
evolve de novo.
CONCLUSION AND OUTLOOK
The intrinsic resistance of Mycobacterium tuberculosis against
many classes of antibiotics, the ever rising numbers of drug-
resistant strains as well as the scarcity of novel antituberculous
compounds is threatening the progress in containing the dis-
ease. The remarkable capability of M. tuberculosis to evolve drug
resistance against all efficacious drugs at low or no cost under-
lines the necessity of a multipronged strategy to reduce the in-
cidence of both drug-susceptible and drug-resistant M. tubercu-
losis variants. Aside from improving the quality of public health
systems in resource-limited settings, novel, cost-effective point-
of-care diagnostic tools, drugs and an effective vaccine are ur-
gently needed. Furthermore, the influence of the strain genetic
background on virtually all aspects of drug resistance evolution
highlights that it is not sufficient to focus research on labora-
tory strains. It is crucial to include M. tuberculosis strains which
ideally represent the whole phylogenetic space of the species in
order to assess the impact of a novel drug, or for thatmatter, any
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planned intervention on the population biology of this extraor-
dinarily successful pathogen.
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